Novartis v. Breckenridge: Obviousness-Type Double Patenting Explained

Without trying to summarize this well-written opinion by Judge Chen, I simply recommend that you store it somewhere and pull it out when you have a tricky obviousness-type double-patenting situation and want a thorough review of the doctrine. The opinion reviews both the facts of the present dispute, which involved pre- and post-URAA filing dates, and of the precedent, a Gilead case and an AbbVie case – with clear charts as well.

This entry was posted in Double Patenting, Obviousness and tagged , , , , , . Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *